<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00744692</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00008753</org_study_id>
    <nct_id>NCT00744692</nct_id>
  </id_info>
  <brief_title>Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders</brief_title>
  <official_title>A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients &lt;21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine the feasibility of attaining acceptable rates of donor
      cell engraftment (&gt;25% donor chimerism at 180 days) following reduced intensity conditioning
      (RIC) regimens in pediatric patients &lt; 21 years receiving cord blood transplantation for
      non-malignant disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myeloablative doses of chemotherapy and/or radiation therapy are employed with the primary
      purpose of eradicating malignant cells. Additionally, these regimens exert varying degree of
      immunosuppression/immunoablation that aids in reducing the likelihood of rejection by host
      hematopoietic cells. However, myeloablative /immunoablative regimens have also been
      associated with significant regimen related toxicity (RRT) and regimen related mortality
      (RRM) that may cause death in up to 20% of patients and significantly higher rate of severe
      organ dysfunction or failure. While most of these RRT occur typically in the first 100 days [
      e.g. VOD (veno occlusive disease), pulmonary or intracranial hemorrhage, multiorgan failure
      (MOF)], there are significant long term toxicities of TBI and/or chemotherapy including
      growth impairment, gonadal dysfunction/failure, hypothyroidism, cataracts, neurocognitive
      impairment, and second malignancies.

      The primary objective is to determine the feasibility of attaining acceptable rates of donor
      cell engraftment (&gt;25% donor chimerism at 180 days) following reduced intensity conditioning
      (RIC) regimens in pediatric patients &lt; 21 years receiving cord blood transplantation for
      non-malignant disorders.

      The secondary objectives are:

        -  To describe the pace of neutrophil and platelet recovery

        -  To evaluate the pace of immune reconstitution.

        -  To determine the treatment related mortality, overall survival and disease free survival
           by days 100 and 180 post-transplant

        -  To describe incidence of acute Graft Versus Host Disease (GVHD) (II - IV) and chronic
           extensive GVHD

        -  To describe the incidence of grade 3-4 organ toxicity

        -  To evaluate long-term complications, such as sterility, endocrinopathy, and growth
           failure

        -  To evaluate the incidence of late graft failures at 2 years post-transplant
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Feasibility of Attaining Acceptable Rates of Donor Cell Engraftment (&gt;25% Donor Cells at 180 Days) Following RIC Regimens in Children &lt; 21 Years Receiving UCBT for Non-malignant Disorders.</measure>
    <time_frame>180 days post transplant</time_frame>
    <description>Determine the feasibility of attaining acceptable rates of donor cell engraftment (&gt;25% donor cells at 180 days) following reduced intensity conditioning regimens in children &lt; 21 years receiving cord blood transplant for non-malignant disorders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Describe the Pace of Neutrophil Recovery</measure>
    <time_frame>42 days post transplant</time_frame>
    <description>Neutrophil recovery was defined as the first day of an absolute neutrophil count (ANC) more than 500/uL for 3 consecutive days not secondary to granulocyte infusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Pace of Immune Reconstitution.</measure>
    <time_frame>1 year post transplant</time_frame>
    <description>Immune reconstitution after RIC in UCBT was described. CD4 count is a standard measure of immune reconstitution and is described here. Additional data is available upon request.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Determine the Overall Survival at day180 Post-transplant</measure>
    <time_frame>180 days</time_frame>
    <description>To determine the overall survival at day180 post-transplant: determined by Kaplan Meier survival analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Describe Incidence of Acute Graft Versus Host Disease (GVHD) (II - IV)</measure>
    <time_frame>100 days post transplant</time_frame>
    <description>To describe incidence of acute Graft Versus Host Disease (GVHD) (II - IV) : measured by cumulative incidence analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Describe the Incidence of Grade 3-4 Organ Toxicity</measure>
    <time_frame>2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate Long-term Complications, Such as Sterility, Endocrinopathy, and Growth Failure</measure>
    <time_frame>at least 2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Incidence of Late Graft Failures at 2 Years Post-transplant</measure>
    <time_frame>2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Describe the Pace of Platelet Recovery</measure>
    <time_frame>180 days post transplant</time_frame>
    <description>Platelet engraftment was defined as the first day of platelet counts more than 50,000/uL for 7 consecutive days without transfusions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Non Malignant Disorders</condition>
  <condition>Immunodeficiencies</condition>
  <condition>Congenital Marrow Failures</condition>
  <condition>Hemoglobinopathies</condition>
  <condition>Inborn Errors of Metabolism</condition>
  <condition>Sickle Cell</condition>
  <condition>Thalassemia</condition>
  <condition>Lysosomal Storage Disease</condition>
  <arm_group>
    <arm_group_label>RIC Cord Blood Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reduced Intensity Conditioning for Umbilical Cord Blood Transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Unrelated Umbilical Cord Blood Transplant</intervention_name>
    <description>Reduced Intensity Conditioning for unrelated umbilical cord blood transplant</description>
    <arm_group_label>RIC Cord Blood Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reduced Intensity Conditioning</intervention_name>
    <arm_group_label>RIC Cord Blood Transplant</arm_group_label>
    <other_name>Campath</other_name>
    <other_name>Hydroxyurea</other_name>
    <other_name>Fludarabine</other_name>
    <other_name>Melphalan</other_name>
    <other_name>Thiotepa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  0-21 years of age with a diagnosis of a immunodeficiency, congenital marrow failure
             syndrome, inborn error of metabolism, or hereditary anemia

          -  Appropriately matched related or unrelated umbilical cord blood unit with a cell dose
             ≥ 3 x 10e7cells/kg

          -  Performance score (lansky or karnofsky) greater than or equal to 70

          -  Adequate organ function (Creatinine ≤ 2.0 mg/dl and creatinine clearance ≥ 50
             ml/min/1.73 m2; Hepatic transaminases (ALT/AST) ≤ 4 x normal; Shortening fraction &gt;26%
             or ejection fraction &gt;40% or &gt; 80% of normal value for age; Pulmonary function tests
             demonstrating CVC or FEV1/FVC of &gt;60% of predicted for age.)

          -  Informed consent

          -  Not pregnant or breast feeding

          -  Minimum life expectancy of at least 6 months

          -  HIV negative

          -  No uncontrolled infections at the time of cytoreduction

          -  Disease specific inclusion criteria

        Exclusion Criteria:

          -  Patients with hemoglobinopathies &gt; 3 years of age

          -  UCB unit with a total nucleated cell count &lt; 3 x 10e7/kg or &gt; 2 antigen mismatching

          -  Available HLA-matched related living donor able to donate without previous UCB
             donation

          -  Allogeneic hematopoietic stem cell transplant within the previous 6 months

          -  Any active malignancy, MDS, or any history of malignancy

          -  Severe acquired aplastic anemia

          -  DLCO &lt; 60% of normal value for age; requirement for supplemental oxygen

          -  Uncontrolled bacterial, viral or fungal infection (currently taking medication and
             progression of clinical symptoms)

          -  Pregnancy or nursing mother

          -  HIV/HTLV seropositive, Hep B surface antigen positive, or HCV RNA positive by PCR

          -  Any condition that precludes serial follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suhag Parikh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Pediatric Blood and Marrow Transplant</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center Pediatric Blood and Marrow Transplant Program</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2008</study_first_submitted>
  <study_first_submitted_qc>August 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2008</study_first_posted>
  <results_first_submitted>July 23, 2014</results_first_submitted>
  <results_first_submitted_qc>July 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 13, 2014</results_first_posted>
  <last_update_submitted>July 23, 2014</last_update_submitted>
  <last_update_submitted_qc>July 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunodeficiencies</keyword>
  <keyword>Congenital Marrow Failures</keyword>
  <keyword>Hemoglobinopathies</keyword>
  <keyword>Inborn Errors of Metabolism</keyword>
  <keyword>SCIDS</keyword>
  <keyword>Wiskott Aldrich</keyword>
  <keyword>FEL</keyword>
  <keyword>HLH</keyword>
  <keyword>IPEX</keyword>
  <keyword>LAD</keyword>
  <keyword>Sickle Cell</keyword>
  <keyword>Thalassemia</keyword>
  <keyword>Omenn's Syndrome</keyword>
  <keyword>Hurler's Syndrome</keyword>
  <keyword>MLD</keyword>
  <keyword>ALD</keyword>
  <keyword>Sanfilippo</keyword>
  <keyword>Krabbe</keyword>
  <keyword>Hunter's syndrome</keyword>
  <keyword>TaySachs</keyword>
  <keyword>Diamond Blackfan Anemia</keyword>
  <keyword>transplant</keyword>
  <keyword>MPS</keyword>
  <keyword>Gaucher</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Lysosomal Storage Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RIC Cord Blood Transplant</title>
          <description>Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
Unrelated Umbilical Cord Blood Transplant: Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
Reduced Intensity Conditioning</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>22 subjects undergoing umbilical cord blood transplant</population>
      <group_list>
        <group group_id="B1">
          <title>RIC Cord Blood Transplant</title>
          <description>Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
Unrelated Umbilical Cord Blood Transplant: Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
Reduced Intensity Conditioning</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age (in years) on the day of transplant</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.83" lower_limit="0.3" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Age (years) on the day of transplant</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determine the Feasibility of Attaining Acceptable Rates of Donor Cell Engraftment (&gt;25% Donor Cells at 180 Days) Following RIC Regimens in Children &lt; 21 Years Receiving UCBT for Non-malignant Disorders.</title>
        <description>Determine the feasibility of attaining acceptable rates of donor cell engraftment (&gt;25% donor cells at 180 days) following reduced intensity conditioning regimens in children &lt; 21 years receiving cord blood transplant for non-malignant disorders.</description>
        <time_frame>180 days post transplant</time_frame>
        <population>Of the 22 patients enrolled, 18 patients were alive at 180 days, the time-point for primary end point</population>
        <group_list>
          <group group_id="O1">
            <title>RIC Cord Blood Transplant</title>
            <description>Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
Unrelated Umbilical Cord Blood Transplant: Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
Reduced Intensity Conditioning</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Feasibility of Attaining Acceptable Rates of Donor Cell Engraftment (&gt;25% Donor Cells at 180 Days) Following RIC Regimens in Children &lt; 21 Years Receiving UCBT for Non-malignant Disorders.</title>
          <description>Determine the feasibility of attaining acceptable rates of donor cell engraftment (&gt;25% donor cells at 180 days) following reduced intensity conditioning regimens in children &lt; 21 years receiving cord blood transplant for non-malignant disorders.</description>
          <population>Of the 22 patients enrolled, 18 patients were alive at 180 days, the time-point for primary end point</population>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Describe the Pace of Neutrophil Recovery</title>
        <description>Neutrophil recovery was defined as the first day of an absolute neutrophil count (ANC) more than 500/uL for 3 consecutive days not secondary to granulocyte infusions</description>
        <time_frame>42 days post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RIC Cord Blood Transplant</title>
            <description>Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
Unrelated Umbilical Cord Blood Transplant: Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
Reduced Intensity Conditioning</description>
          </group>
        </group_list>
        <measure>
          <title>To Describe the Pace of Neutrophil Recovery</title>
          <description>Neutrophil recovery was defined as the first day of an absolute neutrophil count (ANC) more than 500/uL for 3 consecutive days not secondary to granulocyte infusions</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="12" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Pace of Immune Reconstitution.</title>
        <description>Immune reconstitution after RIC in UCBT was described. CD4 count is a standard measure of immune reconstitution and is described here. Additional data is available upon request.</description>
        <time_frame>1 year post transplant</time_frame>
        <population>Of the 22 patients at baseline, 5 patients died early before a year; and 2 additional patients had early graft failure. Thus 7 patients were not available for analysis of Immune reconstitution endpoint. CD4 count is reported here.</population>
        <group_list>
          <group group_id="O1">
            <title>RIC Cord Blood Transplant</title>
            <description>Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
Unrelated Umbilical Cord Blood Transplant: Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
Reduced Intensity Conditioning</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Pace of Immune Reconstitution.</title>
          <description>Immune reconstitution after RIC in UCBT was described. CD4 count is a standard measure of immune reconstitution and is described here. Additional data is available upon request.</description>
          <population>Of the 22 patients at baseline, 5 patients died early before a year; and 2 additional patients had early graft failure. Thus 7 patients were not available for analysis of Immune reconstitution endpoint. CD4 count is reported here.</population>
          <units>cells/uL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="805" lower_limit="6" upper_limit="2013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Overall Survival at day180 Post-transplant</title>
        <description>To determine the overall survival at day180 post-transplant: determined by Kaplan Meier survival analysis</description>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RIC Cord Blood Transplant</title>
            <description>Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
Unrelated Umbilical Cord Blood Transplant: Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
Reduced Intensity Conditioning</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Overall Survival at day180 Post-transplant</title>
          <description>To determine the overall survival at day180 post-transplant: determined by Kaplan Meier survival analysis</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" lower_limit="58.5" upper_limit="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Describe Incidence of Acute Graft Versus Host Disease (GVHD) (II - IV)</title>
        <description>To describe incidence of acute Graft Versus Host Disease (GVHD) (II - IV) : measured by cumulative incidence analysis</description>
        <time_frame>100 days post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RIC Cord Blood Transplant</title>
            <description>Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
Unrelated Umbilical Cord Blood Transplant: Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
Reduced Intensity Conditioning</description>
          </group>
        </group_list>
        <measure>
          <title>To Describe Incidence of Acute Graft Versus Host Disease (GVHD) (II - IV)</title>
          <description>To describe incidence of acute Graft Versus Host Disease (GVHD) (II - IV) : measured by cumulative incidence analysis</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" lower_limit="5.3" upper_limit="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Describe the Incidence of Grade 3-4 Organ Toxicity</title>
        <time_frame>2 years post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RIC Cord Blood Transplant</title>
            <description>Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
Unrelated Umbilical Cord Blood Transplant: Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
Reduced Intensity Conditioning</description>
          </group>
        </group_list>
        <measure>
          <title>To Describe the Incidence of Grade 3-4 Organ Toxicity</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate Long-term Complications, Such as Sterility, Endocrinopathy, and Growth Failure</title>
        <time_frame>at least 2 years post transplant</time_frame>
        <population>Of the 22 patients at baseline, 5 patients died early before a year; and 2 additional patients had early graft failure. Thus 7 patients were not available for analysis of this 2 year late effects endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>RIC Cord Blood Transplant</title>
            <description>Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
Unrelated Umbilical Cord Blood Transplant: Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
Reduced Intensity Conditioning</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate Long-term Complications, Such as Sterility, Endocrinopathy, and Growth Failure</title>
          <population>Of the 22 patients at baseline, 5 patients died early before a year; and 2 additional patients had early graft failure. Thus 7 patients were not available for analysis of this 2 year late effects endpoint.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Incidence of Late Graft Failures at 2 Years Post-transplant</title>
        <time_frame>2 years post transplant</time_frame>
        <population>Of the 22 patients at baseline, 5 patients died early before a year; and 2 additional patients had early graft failure. Thus 7 patients were not available for analysis of this 2 year late graft failure endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>RIC Cord Blood Transplant</title>
            <description>Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
Unrelated Umbilical Cord Blood Transplant: Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
Reduced Intensity Conditioning</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Incidence of Late Graft Failures at 2 Years Post-transplant</title>
          <population>Of the 22 patients at baseline, 5 patients died early before a year; and 2 additional patients had early graft failure. Thus 7 patients were not available for analysis of this 2 year late graft failure endpoint.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Describe the Pace of Platelet Recovery</title>
        <description>Platelet engraftment was defined as the first day of platelet counts more than 50,000/uL for 7 consecutive days without transfusions</description>
        <time_frame>180 days post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RIC Cord Blood Transplant</title>
            <description>Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
Unrelated Umbilical Cord Blood Transplant: Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
Reduced Intensity Conditioning</description>
          </group>
        </group_list>
        <measure>
          <title>To Describe the Pace of Platelet Recovery</title>
          <description>Platelet engraftment was defined as the first day of platelet counts more than 50,000/uL for 7 consecutive days without transfusions</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="33" upper_limit="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events that were expected and non-serious were not collected in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>RIC Cord Blood Transplant</title>
          <description>Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
Unrelated Umbilical Cord Blood Transplant: Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
Reduced Intensity Conditioning</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Auto Immune Hemolytic Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hemolytic Transfusion Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Graft Failure Post Transplant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>GI Distress</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pnematosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi System Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Graft Versus Host Disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>VP Shunt Malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Posterior Reversible Encephalopathy Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrotic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Necrotic Ulcer (skin)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Central Line Removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dental Rehabilitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Suhag Parikh</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-668-1100</phone>
      <email>suhag.parikh@dm.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

